193 related articles for article (PubMed ID: 37674627)
1. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP; Thura M; Gupta A; Tan SH; Kuan KKY; Ang KH; Merchant K; Chang KTE; Yon HY; Chen Y; Cheng MHW; Mahadev A; Ng MCH; Seng MS; Iyer P; Chia PL; Soh SY; Zeng Q
Mol Ther Oncolytics; 2023 Sep; 30():153-166. PubMed ID: 37674627
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; Yang S; Thura M; Al-Aidaroos AQ; Chng WJ; Zeng Q; Goh BC
Target Oncol; 2023 May; 18(3):391-402. PubMed ID: 37060431
[TBL] [Abstract][Full Text] [Related]
3. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2019 Jun; 10(1):2484. PubMed ID: 31171773
[TBL] [Abstract][Full Text] [Related]
4. PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Thura M; Al-Aidaroos AQO; Yong WP; Kono K; Gupta A; Lin YB; Mimura K; Thiery JP; Goh BC; Tan P; Soo R; Hong CW; Wang L; Lin SJ; Chen E; Rha SY; Chung HC; Li J; Nandi S; Yuen HF; Zhang SD; Guan YK; So J; Zeng Q
JCI Insight; 2016 Jun; 1(9):e87607. PubMed ID: 27699276
[TBL] [Abstract][Full Text] [Related]
5. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Jul; 4(1):923. PubMed ID: 34326464
[TBL] [Abstract][Full Text] [Related]
6. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.
Chia PL; Ang KH; Thura M; Zeng Q
Theranostics; 2023; 13(6):1876-1891. PubMed ID: 37064866
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2021 Nov; 12(1):6431. PubMed ID: 34728638
[No Abstract] [Full Text] [Related]
8. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
9. PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
Edwards DR; Moroz K; Zhang H; Mulholland D; Abdel-Mageed AB; Mondal D
Int J Oncol; 2018 Feb; 52(2):402-412. PubMed ID: 29207031
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Nov; 4(1):1282. PubMed ID: 34750497
[No Abstract] [Full Text] [Related]
11. Correlation of PRL3 expression with colorectal cancer progression.
Leiphrakpam PD; Lazenby AJ; Smith LM; Brattain MG; Black JD; Wang J; Are C
J Surg Oncol; 2021 Jan; 123(1):42-51. PubMed ID: 33179291
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling.
Csoboz B; Gombos I; Tatrai E; Tovari J; Kiss AL; Horvath I; Vigh L
Cell Commun Signal; 2018 Aug; 16(1):51. PubMed ID: 30157875
[TBL] [Abstract][Full Text] [Related]
13. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.
Dias P; Parham DM; Shapiro DN; Webber BL; Houghton PJ
Am J Pathol; 1990 Dec; 137(6):1283-91. PubMed ID: 2260621
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.
Sun W; Zhang Y; Wong KC; Liu K; Yang Y; Wu B; Tong JHM; Chan AWH; Chan HLY; Yu J
Hepatology; 2018 Jun; 67(6):2302-2319. PubMed ID: 29266303
[TBL] [Abstract][Full Text] [Related]
15. Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction.
Walls CD; Iliuk A; Bai Y; Wang M; Tao WA; Zhang ZY
Mol Cell Proteomics; 2013 Dec; 12(12):3759-77. PubMed ID: 24030100
[TBL] [Abstract][Full Text] [Related]
16. Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis.
Zhang T; Liu L; Lai W; Zeng Y; Xu H; Lan Q; Su P; Chu Z
Oncol Rep; 2019 May; 41(5):2790-2802. PubMed ID: 30864736
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
18. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
19. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Liang F; Liang J; Wang WQ; Sun JP; Udho E; Zhang ZY
J Biol Chem; 2007 Feb; 282(8):5413-9. PubMed ID: 17192274
[TBL] [Abstract][Full Text] [Related]
20. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase.
Liang F; Luo Y; Dong Y; Walls CD; Liang J; Jiang HY; Sanford JR; Wek RC; Zhang ZY
J Biol Chem; 2008 Apr; 283(16):10339-46. PubMed ID: 18268019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
